Country: Canada
Language: English
Source: Health Canada
LEFLUNOMIDE
TEVA CANADA LIMITED
L04AK01
LEFLUNOMIDE
20MG
TABLET
LEFLUNOMIDE 20MG
ORAL
30/100
Prescription
DISEASE-MODIFYING ANTIRHEUMATIC AGENTS
Active ingredient group (AIG) number: 0140182002; AHFS:
APPROVED
2004-12-10
TEVA-LEFLUNOMIDE Page 1 of 77 PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR TEVA-LEFLUNOMIDE Leflunomide Tablets Film-coated tablets, 10 mg and 20 mg, Oral Teva Standard Antirheumatic, Immunomodulator Agent Teva Canada Limited Date of Initial Authorization: 30 Novopharm Court December 10, 2004 Toronto, ON M1B 2K9 Date of Revision: Canada June 5, 2023 www.tevacanada.com Submission Control Number: 270353 2 RECENT MAJOR LABEL CHANGES 7 WARNINGS AND PRECAUTIONS 05/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ............................................................................................ 2 TABLE OF CONTENTS .............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ...................................................................... 4 1 INDICATIONS ........................................................................................................... 4 1.1 Pediatrics ............................................................................................................. 4 1.2 Geriatrics ............................................................................................................. 4 2 CONTRAINDICATIONS .............................................................................................. 4 4 DOSAGE AND ADMINISTRATION .............................................................................. 5 4.2 Recommended Dose and Dosage Adjustment ................................................... 5 4.4 Administration .................................................................................................... 6 4.5 Missed Dose ........................................................................................................ 6 5 OVERDOSAGE .......................................................................................................... 6 6 DOSAGE FORMS, S Read the complete document